139 related articles for article (PubMed ID: 38682544)
1. Industrial and academic approaches to the search for alternative melatonin receptor ligands: An historical survey.
Bedini A; Boutin JA; Legros C; Zlotos DP; Spadoni G
J Pineal Res; 2024 May; 76(4):e12953. PubMed ID: 38682544
[TBL] [Abstract][Full Text] [Related]
2. Virtual discovery of melatonin receptor ligands to modulate circadian rhythms.
Stein RM; Kang HJ; McCorvy JD; Glatfelter GC; Jones AJ; Che T; Slocum S; Huang XP; Savych O; Moroz YS; Stauch B; Johansson LC; Cherezov V; Kenakin T; Irwin JJ; Shoichet BK; Roth BL; Dubocovich ML
Nature; 2020 Mar; 579(7800):609-614. PubMed ID: 32040955
[TBL] [Abstract][Full Text] [Related]
3. New selective ligands of human cloned melatonin MT1 and MT2 receptors.
Audinot V; Mailliet F; Lahaye-Brasseur C; Bonnaud A; Le Gall A; Amossé C; Dromaint S; Rodriguez M; Nagel N; Galizzi JP; Malpaux B; Guillaumet G; Lesieur D; Lefoulon F; Renard P; Delagrange P; Boutin JA
Naunyn Schmiedebergs Arch Pharmacol; 2003 Jun; 367(6):553-61. PubMed ID: 12764576
[TBL] [Abstract][Full Text] [Related]
4. Melatonin receptor ligands: A pharmaco-chemical perspective.
Boutin JA; Witt-Enderby PA; Sotriffer C; Zlotos DP
J Pineal Res; 2020 Oct; 69(3):e12672. PubMed ID: 32531076
[TBL] [Abstract][Full Text] [Related]
5. Melatonin MT
López-Canul M; Min SH; Posa L; De Gregorio D; Bedini A; Spadoni G; Gobbi G; Comai S
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31108968
[TBL] [Abstract][Full Text] [Related]
6. Docking studies for melatonin receptors.
Alkozi HA; Sánchez Montero JM; Doadrio AL; Pintor J
Expert Opin Drug Discov; 2018 Mar; 13(3):241-248. PubMed ID: 29271261
[TBL] [Abstract][Full Text] [Related]
7. A molecular and chemical perspective in defining melatonin receptor subtype selectivity.
Chan KH; Wong YH
Int J Mol Sci; 2013 Sep; 14(9):18385-406. PubMed ID: 24018885
[TBL] [Abstract][Full Text] [Related]
8. High-throughput screening assay for new ligands at human melatonin receptors.
Yan JH; Su HR; Boutin JA; Renard MP; Wang MW
Acta Pharmacol Sin; 2008 Dec; 29(12):1515-21. PubMed ID: 19026172
[TBL] [Abstract][Full Text] [Related]
9. Melatonin receptors as therapeutic targets in the suprachiasmatic nucleus.
Pévet P
Expert Opin Ther Targets; 2016 Oct; 20(10):1209-18. PubMed ID: 27082492
[TBL] [Abstract][Full Text] [Related]
10. Melatonergic ligands: Design, synthesis and pharmacological evaluation of novel series of naphthofuranic derivatives.
Landagaray E; Ettaoussi M; Duroux R; Boutin JA; Caignard DH; Delagrange P; Melnyk P; Berthelot P; Yous S
Eur J Med Chem; 2016 Feb; 109():360-70. PubMed ID: 26820449
[TBL] [Abstract][Full Text] [Related]
11. Tricyclic alkylamides as melatonin receptor ligands with antagonist or inverse agonist activity.
Lucini V; Pannacci M; Scaglione F; Fraschini F; Rivara S; Mor M; Bordi F; Plazzi PV; Spadoni G; Bedini A; Piersanti G; Diamantini G; Tarzia G
J Med Chem; 2004 Aug; 47(17):4202-12. PubMed ID: 15293992
[TBL] [Abstract][Full Text] [Related]
12. New radioligands for describing the molecular pharmacology of MT1 and MT2 melatonin receptors.
Legros C; Matthey U; Grelak T; Pedragona-Moreau S; Hassler W; Yous S; Thomas E; Suzenet F; Folleas B; Lefoulon F; Berthelot P; Caignard DH; Guillaumet G; Delagrange P; Brayer JL; Nosjean O; Boutin JA
Int J Mol Sci; 2013 Apr; 14(5):8948-62. PubMed ID: 23698757
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and functional characterization of substituted isoquinolinones as MT2-selective melatoninergic ligands.
Hu Y; Chan KH; He X; Ho MK; Wong YH
PLoS One; 2014; 9(12):e113638. PubMed ID: 25479338
[TBL] [Abstract][Full Text] [Related]
14. MT1 and MT2 melatonin receptors: ligands, models, oligomers, and therapeutic potential.
Zlotos DP; Jockers R; Cecon E; Rivara S; Witt-Enderby PA
J Med Chem; 2014 Apr; 57(8):3161-85. PubMed ID: 24228714
[TBL] [Abstract][Full Text] [Related]
15. MT1 and MT2 Melatonin Receptors: A Therapeutic Perspective.
Liu J; Clough SJ; Hutchinson AJ; Adamah-Biassi EB; Popovska-Gorevski M; Dubocovich ML
Annu Rev Pharmacol Toxicol; 2016; 56():361-83. PubMed ID: 26514204
[TBL] [Abstract][Full Text] [Related]
16. Molecular cloning and pharmacological characterization of rat melatonin MT1 and MT2 receptors.
Audinot V; Bonnaud A; Grandcolas L; Rodriguez M; Nagel N; Galizzi JP; Balik A; Messager S; Hazlerigg DG; Barrett P; Delagrange P; Boutin JA
Biochem Pharmacol; 2008 May; 75(10):2007-19. PubMed ID: 18384758
[TBL] [Abstract][Full Text] [Related]
17. Binding and unbinding of potent melatonin receptor ligands: Mechanistic simulations and experimental evidence.
Bedini A; Elisi GM; Fanini F; Retini M; Scalvini L; Pasquini S; Contri C; Varani K; Spadoni G; Mor M; Vincenzi F; Rivara S
J Pineal Res; 2024 Mar; 76(2):e12941. PubMed ID: 38606814
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in melatonin receptor ligands.
Zlotos DP
Arch Pharm (Weinheim); 2005 Jun; 338(5-6):229-47. PubMed ID: 15952241
[TBL] [Abstract][Full Text] [Related]
19. Strategies leading to MT2 selective melatonin receptor antagonists.
Spadoni G; Bedini A; Piersanti G; Mor M; Rivara S; Tarzia G
Adv Exp Med Biol; 2003; 527():577-85. PubMed ID: 15206776
[TBL] [Abstract][Full Text] [Related]
20. MT1-selective melatonin receptor ligands: synthesis, pharmacological evaluation, and molecular dynamics investigation of N-{[(3-O-substituted)anilino]alkyl}amides.
Rivara S; Pala D; Lodola A; Mor M; Lucini V; Dugnani S; Scaglione F; Bedini A; Lucarini S; Tarzia G; Spadoni G
ChemMedChem; 2012 Nov; 7(11):1954-64. PubMed ID: 22927210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
